Poolbeg Pharma has reached an important clinical milestone with its UK trial of POLB 001, an investigational treatment being developed to help prevent cytokine release syndrome (CRS) in patients receiving certain cancer immunotherapies.

The Dublin-headquartered clinical-stage biopharmaceutical company announced that the interim safety cohort in its TOPICAL trial had been reviewed positively, with the study recommended to continue as planned and no changes required to the study protocol. Patient recruitment is continuing across UK clinical sites. Poolbeg Pharma’s announcement describes the review as an important milestone in the programme.

The trial is evaluating POLB 001 as a preventative therapy for CRS in patients with relapsed or refractory multiple myeloma receiving teclistamab, an approved bispecific antibody used to treat the blood cancer.

For Health & Safety professionals working in healthcare, the development is particularly relevant because CRS can be a potentially serious reaction to some cancer immunotherapies. It can involve fever, low blood pressure and other systemic effects, making early recognition and appropriate clinical intervention important to patient safety.

The Irish Independent reported that Poolbeg sees potential for POLB 001 to reduce the severity of CRS associated with cancer immunotherapies. If successfully developed, the company believes the treatment could help make some therapies safer and potentially support their use outside highly specialised centres. That remains a future possibility rather than an established clinical outcome.

The research is being conducted across leading UK clinical sites, including The Christie in Manchester, Royal Marsden and University College London Hospitals. The Christie is one of the UK's major specialist cancer centres and has extensive experience in delivering innovative cancer treatments and clinical trials.

Poolbeg is also involved in the UK Medical Research Council-supported RISE programme, which is investigating approaches to reduce treatment-related complications associated with immunotherapies. Its POLB 001 oncology programme forms part of the company’s wider strategy to develop therapies addressing unmet clinical needs.

For the sector, the development highlights how pharmaceutical innovation can directly support patient safety. As advanced cancer therapies become more widely used, preventative approaches to treatment-related complications could help create safer clinical pathways while potentially expanding access to specialist therapies.

Source: Irish Independent / Poolbeg Pharma / The Christie